Characterization of factor VIII/von Willebrand factor concentrates using a modified method of von Willebrand factor multimer analysis
- 1 November 1998
- journal article
- research article
- Published by Wiley in Haemophilia
- Vol. 4 (S3) , 25-32
- https://doi.org/10.1046/j.1365-2516.1998.0040s3025.x
Abstract
In order to provide patients with von Willebrand disease a factor VIII (FVIII)/von Willebrand factor (vWF) concentrate of reproducible quality, an SDS-agarose gel electrophoresis method has been established to determine the content of the high molecular weight multimers (band 11 and higher) of vWF. This method has been used to characterize the content of high molecular weight vWF multimers in Humate® P/Haemate® P, a commercial FVIII/vWF concentrate. The average content of high molecular weight vWF multimers of 47 batches of Humate® P/Haemate® P has been determined to be 84.1% of the corresponding bands in normal human plasma. Use of this multimer analysis method for the characterization of five further commercial products revealed clear differences with respect to the high molecular weight vWF multimer content. Furthermore, there is a linear correlation (r2 = 0.73) between the content of high molecular weight vWF multimers and the specific activity of vWF (determined as vWF:RCoF/vWF:Ag). The method described here for analysis of the content of high molecular weight vWF multimers is a reliable and reproducible method to characterize this class of factor concentrates with respect to vWF multimer composition.Keywords
This publication has 28 references indexed in Scilit:
- EFFECT OF MULTIMERIZATION OF HUMAN AND RECOMBINANT VON WILLEBRAND FACTOR ON PLATELET AGGREGATION, BINDING TO COLLAGEN AND BINDING OF COAGULATION FACTOR VIIIThrombosis Research, 1996
- A Technique for von Willebrand Multimer Analysis Applicable to the Clinical LaboratoryClinical and Applied Thrombosis/hemostasis, 1995
- Therapy of von Willebrand DiseaseSeminars in Thrombosis and Hemostasis, 1993
- Use of a High‐Purity Factor VIII Concentrate (Hemate P) in von Willebrand's Disease1Vox Sanguinis, 1989
- Characterization of von willebrand factor in factor VIII concentratesAmerican Journal of Hematology, 1989
- Absence of Hepatitis after Treatment with a Pasteurized Factor VIII Concentrate in Patients with Hemophilia and No Previous TransfusionsNew England Journal of Medicine, 1987
- Platelet interaction with rabbit subendothelium in von Willebrand's disease: altered thrombus formation distinct from defective platelet adhesion.Journal of Clinical Investigation, 1984
- Preferential binding of high molecular weight forms of von Willebrand factor to fibrillar collagen☆Biochimica et Biophysica Acta (BBA) - General Subjects, 1983
- Variant von Willebrand's DiseaseJournal of Clinical Investigation, 1980
- Stabilization of Factor VIII in Plasma by the von Willebrand FactorJournal of Clinical Investigation, 1977